Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026)
Bristol Myers Squibb (BMY) reported Land & Improvements of $157.0 million for Q1 2026, little changed quarter-over-quarter from $157.0 million in Q4 2025.
Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has 2 years of Land & Improvements data on file, last reported at $157.0 million in Q1 2026.
- Land & Improvements for Q1 2026 came in at $157.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $157.0 million (changed N/A YoY), and the FY2025 annual result was $157.0 million, changed N/A from the prior year.
- Land & Improvements was little changed at $157.0 million in Q1 2026 per BMY's latest filing, from $157.0 million in the prior quarter.
- Over five years, Land & Improvements peaked at $157.0 million in Q4 2025 and troughed at $157.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |